Braveheart Bio (NASDAQ:BRVE) Stock Jumps 4.3% - Here's Why

Braveheart Bio logo with background
Image from MarketBeat Media, LLC.

Key Points

  • Braveheart Bio shares rose 4.3% to about $20.10 Friday, while trading volume was 68% below its average.
  • Analysts’ consensus rating is “Moderate Buy”, with a $45.25 average price target; five analysts rate the stock Buy, one Hold, and one Sell.
  • The company reported a quarterly loss of $0.51 per share, narrower than the $0.91 loss analysts expected.
  • Five stocks to consider instead of Braveheart Bio.

Braveheart Bio, Inc. (NASDAQ:BRVE - Get Free Report) shares were up 4.3% during trading on Friday. The stock traded as high as $20.14 and last traded at $20.0960. 151,967 shares traded hands during trading, a decline of 68% from the average daily volume of 470,956 shares. The stock had previously closed at $19.27.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Jefferies Financial Group began coverage on Braveheart Bio in a research report on Monday, August 31st. They issued a "buy" rating and a $48.00 target price on the stock. Zacks Research upgraded Braveheart Bio to a "hold" rating in a research report on Tuesday, September 1st. TD Cowen initiated coverage on Braveheart Bio in a research note on Monday, August 31st. They issued a "buy" rating for the company. Stifel Nicolaus initiated coverage on shares of Braveheart Bio in a report on Monday, August 31st. They issued a "buy" rating and a $45.00 target price on the stock. Finally, Weiss Ratings initiated coverage on Braveheart Bio in a research report on Monday, November 2nd. They set a "sell (d-)" rating on the stock. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $45.25.

Read Our Latest Stock Report on BRVE

Braveheart Bio Trading Up 7.8%

The firm has a fifty day moving average price of $21.35. The stock has a market cap of $1.87 billion and a price-to-earnings ratio of -6.77.

Braveheart Bio (NASDAQ:BRVE - Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.91) by $0.40. As a group, sell-side analysts forecast that Braveheart Bio, Inc. will post -1.97 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Readystate Asset Management LP bought a new stake in Braveheart Bio in the 3rd quarter valued at $202,000. Ghisallo Capital Management LLC bought a new position in shares of Braveheart Bio during the third quarter worth $404,000. Goldman Sachs Group Inc. bought a new stake in Braveheart Bio during the 3rd quarter worth approximately $841,000. Integral Health Asset Management LLC acquired a new stake in Braveheart Bio in the 3rd quarter valued at approximately $2,020,000. Finally, RA Capital Management L.P. bought a new stake in Braveheart Bio during the third quarter worth about $11,413,000.

Braveheart Bio Company Profile

(Get Free Report)

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Braveheart Bio Right Now?

Before you consider Braveheart Bio, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Braveheart Bio wasn't on the list.

While Braveheart Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines